Current:Home > FinanceCDC recommends first RSV vaccines for some seniors-LoTradeCoin
CDC recommends first RSV vaccines for some seniors
View Date:2024-12-23 18:45:26
The first vaccines to guard against the respiratory illness RSV will soon be available for some older adults, ages 60 and over, after the CDC formally backed recommendations for the shots.
The move, announced Thursday, followed a vote at a meeting of the CDC's Advisory Committee on Immunization Practices earlier this month on the new vaccines, and will trigger federal requirements on insurance coverage of vaccinations. The FDA approved the shots, GSK's Arexvy and Pfizer's Abrysvo, earlier this year.
The new guidance stops short of a full-throated recommendation for all eligible older adults to get the shots. Instead, the panel called for "shared clinical decision-making" between doctors and patients to decide whether the individual benefits outweigh the risks.
"This means these individuals may receive a single dose of the vaccine based on discussions with their healthcare provider about whether RSV vaccination is right for them," the CDC said in a statement.
Among seniors, those in their early 60s are less likely to face severe disease from RSV — which stands for respiratory syncytial virus — compared to their oldest peers. A handful of very rare cases of severe "inflammatory neurologic events" were also reported in vaccine trials, narrowing the balance of benefits versus risks.
The potential side effects are so rare that assessing whether they are simply "due to random chance" will not be possible until studies done after the shots are rolled out, scrutinizing large databases of health records from people who received the vaccines.
CDC officials assured the panel that they would closely follow data from their vaccine safety systems on the launch of the two new RSV vaccines.
"I want to remind everyone that we have one of the best vaccine safety systems in the world. We have the ability to rapidly acquire information, rapidly assess it, and act on it. We saw that during the COVID pandemic, that system is viable, and is in place," the CDC's Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, told the panel.
Vaccine makers are still studying when seniors might need to come back for a booster dose of RSV vaccine in the coming years. They also have yet to decide on a final price, further complicating broader recommendations.
GSK said their vaccine could be priced between $200 and $295 per dose, higher than they initially told the committee, given new data suggesting the vaccine could offer protection through at least two RSV seasons. Pfizer said their shots could be between $180 to $270.
At higher prices, federal modeling led some on the panel to worry the shots might not be cost-effective as "a reasonable and efficient allocation of resources," especially for the youngest of those approved to get the shots.
A delay to the vote was floated during the meeting, pending the final prices locked in by each drugmaker.
However, time will be of the essence to roll out shots to those most at risk, some said. RSV vaccines will be most effective at saving lives if given before infections climb, which happened unusually early last year.
"Lives, hospitalizations, we could have a significant impact this year. So that's why we wouldn't want to delay further," said Dr. Camille Kotton, chair of the committee's work group on the issue, during the meeting.
Kotton pointed to further studies that are expected to yield results on RSV in the coming years, as well as additional new vaccines in the pipeline.
Doctors and vaccine makers are generally not required to follow the CDC's recommendations on how to use approved vaccines. However, so-called "off-label" use — such as vaccinating those under 60 years old with the RSV shots — may not be covered by insurance.
The FDA is also expected to decide on new approval of the first options to protect infants from RSV later this year. The ACIP is also preparing to eventually vote on those too.
"This field will undoubtedly change within the next five to 10 years. We'll learn a lot more. So we're trying to make a decision as best we can with the data we have now, at this time," Kotton said.
- In:
- RSV
- Vaccine
- Respiratory Syncytial Virus
CBS News reporter covering public health and the pandemic.
veryGood! (15)
Related
- 'Devastation is absolutely heartbreaking' from Southern California wildfire
- Commission on Civil Rights rings alarm bell on law enforcement use of AI tool
- Volunteers help seedlings take root as New Mexico attempts to recover from historic wildfire
- Emory Callahan Introduction
- Watch a rescuer’s cat-like reflexes pluck a kitten from mid-air after a scary fall
- Harris is more popular than Trump among AAPI voters, a new APIA Vote/AAPI Data survey finds
- Connie Chung on the ups and downs of trailblazing career in new memoir | The Excerpt
- 'Boy Meets World' star Trina McGee suffers miscarriage after getting pregnant at age 54
- Pie, meet donuts: Krispy Kreme releases Thanksgiving pie flavor ahead of holidays
- Review: Zachary Quinto medical drama 'Brilliant Minds' is just mind-numbing
Ranking
- Digital Finance Research Institute Introduce
- Lady Gaga Reveals Surprising Person Who Set Her Up With Fiancé Michael Polansky
- Brian Laundrie Attempts to Apologize to Gabby Petito’s Mom Through Psychic
- Boyd Gaming buys Resorts Digital online gambling operation
- John Krasinski named People's Sexiest Man Alive for 2024
- Tennessee replaces Alabama in top four of college football's NCAA Re-Rank 1-134
- As he welcomes Gotham FC, Biden says “a woman can do anything a man can do,” including be president
- Colorado men tortured their housemate for 14 hours, police say
Recommendation
-
How Leonardo DiCaprio Celebrated His 50th Birthday
-
One of Titan submersible owner’s top officials to testify before the Coast Guard
-
Attorneys say other victims could sue a Mississippi sheriff’s department over brutality
-
Volunteers help seedlings take root as New Mexico attempts to recover from historic wildfire
-
RHOBH's Kyle Richards Shares Reaction to BFF Teddi Mellencamp's Divorce
-
'Go into hurricane mode now': Helene expected to lash Florida this week
-
Violent crime dropped for third straight year in 2023, including murder and rape
-
'Emily in Paris' star Lucas Bravo is more than a heartthrob: 'Mystery is sexy'